Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Labcorp exceeded Q2 2026 estimates with strong revenue and adjusted EPS, leading to a lifted full-year outlook. The company reported adjusted EPS of $4.99 and revenue of $3.73 billion, driven by solid organic growth, margin expansion, and strong performance in specialty testing and biopharma …
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1%Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $23.25, reflecting a significant 120.31% increase over the past year. Despite its robust revenue growth of 56% over the last twelve months, InvestingPro analytical data suggests the stock might be overvalued. Recent Q2 results showed …
Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NASDAQ:NTRA), sold 1,718 shares for $447,523 to cover tax obligations related to restricted stock units. This sale comes as Natera shares have risen 80% over the past year, though InvestingPro suggests the stock is overvalued. …
Natera, Inc.'s CFO, Brophy Michael Burkes, sold a total of 5,064 shares of common stock between July 27-29, 2026, through open-market transactions. These sales, executed under a Rule 10b5-1 trading plan adopted in 2025, included shares sold to cover tax withholding obligations related to …
Medpace Holdings's President & CEO, August J Troendle, sold 7,238 shares of company stock worth $4.35 million on July 29, 2026, according to an SEC filing. Despite this insider sale, the company reported strong revenue growth of 17.24% for the quarter ending June 30, …
Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2026 sales of $190.7 million, falling short of analyst estimates, and a non-GAAP loss of $0.25 per share, significantly below consensus. The company also lowered its full-year revenue guidance to $780 million at the midpoint from an earlier $870 …
CareDx, Inc. (CDNA) reported strong second-quarter 2026 results with revenue of $131.95 million and diluted EPS of $2.07. This performance was significantly boosted by higher testing services volume, prior-period collections, and a one-time gain of approximately $113 million from the sale of its lab …
Veracyte, Inc. (VCYT) saw its shares advance significantly during Q2 2026 due to a strong earnings beat and raised full-year guidance, driven by double-digit volume growth in its Decipher test and improved Afirma performance. Meridian Small Cap Growth Fund highlighted VCYT as a key …
HC Wainwright has increased its FY2026 EPS estimate for OPKO Health to a loss of $0.23 per share from $0.30, while maintaining a "Buy" rating. This upgrade follows OPKO's recent quarterly results, which surpassed expectations with a $0.01-per-share loss against an estimated $0.08 loss …
William Blair has initiated coverage on Icon PLC (ICLR.US) with a Buy rating. This indicates a positive outlook from the investment firm regarding the company's stock performance.
Labcorp (NYSE:LH) reported Q2 CY2026 results, meeting revenue expectations with $3.73 billion and beating adjusted EPS estimates at $4.99 per share. The company slightly increased its full-year revenue and Adjusted EPS guidance, demonstrating continued momentum despite a slight post-earnings stock dip. While long-term revenue …
Icon PLC (ICLR) shares recently fell 7.1% to $165.53, yet the company holds a strong GF Score of 88/100, indicating solid fundamentals and growth potential. Despite a high historical P/E, ICLR is considered "modestly undervalued" by GuruFocus, with a GF Value of $227.59, suggesting …
Deutsche Bank has downgraded Option Care Health (OPCH) from a "Buy" rating to "Hold" and reduced its price target from $26 to $24. This action indicates a revised outlook on the stock's performance. Previously, Stephens also downgraded Option Care to "Equal Weight" from "Overweight" …
Prenetics (NASDAQ: PRE) has filed an amendment to its 2025 annual report, clarifying its holding-company structure, intra-group cash flows, non-IFRS indicators, and risks associated with Hong Kong and the PRC. The company also disclosed substantial net losses from 2023-2025 due to marketing investments for …
IQVIA (IQV) stock has experienced a significant surge, climbing 25% over five consecutive trading days, adding $8.1 billion to its market value. This strong performance, which outpaced the S&P 500's decline during the same period, is supported by the company's slightly faster-than-market revenue growth …
A national Health Trends® study by Quest Diagnostics and Hologic, Inc. found that women testing positive for bacterial vaginosis (BV) were over three times more likely to also have non-viral sexually transmitted infections (STIs). The study, which analyzed data from 1.5 million women between …
A national study by Quest Diagnostics and Hologic, analyzing data from over 1.5 million U.S. women, found that 12% of women positive for bacterial vaginosis (BV) also had at least one non-viral sexually transmitted infection (STI), compared to 3.8% of BV-negative women. BV positivity …
The diagnostics and research supplier is extending a three-month advance, though the trend screen has not turned active.
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld …
Guardant Health (GH) reported a Q2 loss of $0.42 per share, which was worse than the Zacks Consensus Estimate of a $0.40 loss, but its revenues of $334.98 million surpassed estimates by 6.01%. Despite outperforming the market year-to-date, the stock currently holds a Zacks …
Labcorp reported strong second-quarter 2026 results, with revenue of $3.73 billion and adjusted diluted EPS of $4.99, marking a 14.9% year-over-year increase. The company raised its full-year 2026 guidance for both enterprise revenue growth and adjusted EPS, and announced a $1.0 billion increase in …
ICON reported strong Q1 2026 financial results, with gross bookings up 22% year-over-year and net business wins of $2.88 billion. The company reaffirmed its full-year 2026 guidance for revenue and adjusted diluted EPS, expecting modest sequential margin improvement. Strategic investments in central labs, oncology …
Labcorp (LH) reported a 5.8% increase in second-quarter 2026 revenue to $3.73 billion, with diluted EPS rising to $3.64. The company raised its full-year revenue and adjusted EPS guidance and announced a $1.0 billion increase in its share repurchase authorization. Insider trading data shows …
Labcorp reported strong second-quarter 2026 results with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth. The company raised its full-year 2026 guidance, reflecting continued momentum in its business operations. Key strategic advancements include expanding oncology offerings, strengthening partnerships with health systems, …
The global prenatal and reproductive genetic testing market was valued at USD 7.8 billion in 2025 and is projected to reach USD 22.4 billion by 2035, growing at a CAGR of 11.2%. This growth is driven by increasing demand for early genetic risk assessment, …
Sharemaestro market context Trend signal active 52 weeks +87.2% · Next-week setup positive 57.5%Labcorp Holdings (LH) reported second-quarter EPS of $4.99, exceeding analyst estimates by $0.20, and revenue of $3.73 billion, surpassing the consensus of $3.71 billion. The company also provided a positive FY 2026 EPS guidance of $18.10-$18.55, higher than the analyst consensus. Labcorp's stock has …
Revvity's stock valuation shows a mixed picture: a Discounted Cash Flow (DCF) analysis suggests it could be 22% undervalued, implying an intrinsic value of $145 per share, while its P/E ratio of 52.9x indicates overvaluation compared to the industry average. The company's share price …
Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading …
CareDx, Inc. (CDNA) had approximately 805 total employees worldwide as of March 2026, marking a 14.9% growth from 700 employees in 2023. The company is actively hiring, with 92 active job postings in 2026, though this represents a 28.0% decline from 2025. CareDx's workforce …
JP Morgan has increased its target price for Quest Diagnostics Inc. from $220 to $250. This change in target price suggests an updated positive outlook for the company's stock by the financial institution. The specific reasons for this revised target are not detailed in …
TradingKey provides a comprehensive stock analysis of Acadia Healthcare Company Inc (ACHC), highlighting its stable fundamentals, significant growth potential, and "fairly valued" status within the Healthcare Providers & Services industry. The report notes high institutional ownership and recent "Buy" ratings from analysts, with a …
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1%Royal Bank of Canada increased its stake in Labcorp Holdings Inc. by 19.4%, acquiring an additional 133,549 shares, bringing its total to 820,442 shares valued at approximately $218.9 million. Labcorp surpassed quarterly earnings expectations with $4.25 EPS and $3.54 billion in revenue, leading to …
Maverick Capital Ltd. significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 90.9% in the first quarter, now holding 1,596 shares valued at $426,000. Despite this reduction, Labcorp reported strong financial results, beating EPS estimates with $4.25 and growing revenue by 5.8% to …
This article provides a comprehensive stock analysis of Oncology Institute Inc (TOI), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes a high institutional ownership and a positive outlook from analysts, with a highest …
Sharemaestro market context Trend signal active 52 weeks +31.8% · Next-week setup positive 58.1%Search by ticker symbol or company name and select a result to open its chart.